文献速递脑血管病神经重症与神经感染

院前经皮硝酸甘油治疗超急性期脑出血:RIGHT-2试验数据

Prehospital Transdermal Glyceryl Trinitrate for Ultra-Acute Intracerebral Hemorrhage: Data From the RIGHT-2 Trial.
PubMed 文献 · Stroke · 2019-10-07

RIGHT-2试验是一项多中心、急救人员实施、救护车内的前瞻性随机假对照盲终点试验,纳入疑似卒中4小时内的成人,比较经皮硝酸甘油(5 mg)与假敷料。预设亚组分析聚焦145例脑出血患者,发现硝酸甘油组90天改良Rankin量表评分无显著升高(调整共同OR 1.87,95%CI 0.98-3.57),但预设全局分析显示结局更差(Mann-Whitney差异0.18,95%CI 0.01-0.35),且血肿更大、占位效应更明显。结论认为院前硝酸甘油治疗脑出血患者结局恶化,需进一步随机证据。

要点

  • 院前经皮硝酸甘油(5 mg)在超急性期脑出血患者中可能导致90天功能结局更差。
  • 硝酸甘油组神经影像显示血肿更大、血肿增长更多、占位效应和中线移位更明显。
  • 预设全局分析(依赖、残疾、认知、生活质量、情绪)显示硝酸甘油组更差。

核心结论

  • 院前硝酸甘油治疗超急性期脑出血患者结局恶化,但结果可能受偶然性、混杂或药物真实效应影响,需进一步随机证据。

研究设计与样本

  • 多中心、急救人员实施、救护车内的前瞻性随机假对照盲终点试验,纳入疑似卒中4小时内成人,预设亚组分析聚焦145例脑出血患者(硝酸甘油74例,假敷料71例)。

主要发现

  • 90天改良Rankin量表评分在硝酸甘油组无显著升高:调整共同OR为1.87(95%CI 0.98-3.57)。
  • 预设全局分析(依赖、残疾、认知、生活质量、情绪)显示硝酸甘油组更差:Mann-Whitney差异0.18(95%CI 0.01-0.35;Wei-Lachin检验)。
  • 硝酸甘油与神经影像上更大的血肿和血肿增长、更明显的占位效应和中线移位相关,并改变医院资源使用。
  • 硝酸甘油组院内死亡增加,但90天死亡无显著差异;严重不良事件组间无显著差异。

临床怎么用

  • 超急性期脑出血患者不应常规院前使用经皮硝酸甘油,因其可能恶化功能结局。

局限性

  • 结果为预设亚组分析,样本量有限(145例脑出血),可能受偶然性、混杂或真实效应影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Pilot trials suggest that glyceryl trinitrate (GTN; nitroglycerin) may improve outcome when administered early after stroke onset. Methods- We undertook a multicentre, paramedic-delivered, ambulance-based, prospective randomized, sham-controlled, blinded-end point trial in adults with presumed stroke within 4 hours of ictus. Participants received transdermal GTN (5 mg) or a sham dressing (1:1) in the ambulance and then daily for three days in hospital. The primary outcome was the 7-level modified Rankin Scale at 90 days assessed by central telephone treatment-blinded follow-up. This prespecified subgroup analysis focuses on participants with an intracerebral hemorrhage as their index event. Analyses are intention-to-treat. Results- Of 1149 participants with presumed stroke, 145 (13%; GTN, 74; sham, 71) had an intracerebral hemorrhage: time from onset to randomization median, 74 minutes (interquartile range, 45-110). By admission to hospital, blood pressure tended to be lower with GTN as compared with sham: mean, 4.4/3.5 mm Hg. The modified Rankin Scale score at 90 days was nonsignificantly higher in the GTN group: adjusted common odds ratio for poor outcome, 1.87 (95% CI, 0.98-3.57). A prespecified global analysis of 5 clinical outcomes (dependency, disability, cognition, quality of life, and mood) was worse with GTN; Mann-Whitney difference, 0.18 (95% CI, 0.01-0.35; Wei-Lachin test). GTN was associated with larger hematoma and growth, and more mass effect and midline shift on neuroimaging, and altered use of hospital resources. Death in hospital but not at day 90 was increased with GTN. There were no significant between-group differences in serious adverse events. Conclusions- Prehospital treatment with GTN worsened outcomes in patients with intracerebral hemorrhage. Since these results could relate to the play of chance, confounding, or a true effect of GTN, further randomized evidence on the use of vasodilators in ultra-acute intracerebral hemorrhage is needed. Clinical Trial Registration- URL: http://www.controlled-trials.com. Unique identifier: ISRCTN26986053.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Bath PM, Woodhouse LJ, Krishnan K, et al. Prehospital Transdermal Glyceryl Trinitrate for Ultra-Acute Intracerebral Hemorrhage: Data From the RIGHT-2 Trial. Stroke. 2019. PMID: 31587658. doi:10.1161/STROKEAHA.119.026389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。